Myomo (MYO) Income from Continuing Operations (2016 - 2025)
Myomo's (MYO) quarterly Income from Continuing Operations came in at -$3.7 million in Q3 2025, down 279.02% on a YoY basis from $2.0 million in Q3 2024, and up 20.92% quarter-over-quarter from -$4.6 million in Q2 2025.
Powered by 
Analysis
Myomo (MYO) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Myomo (MYO) has reported Income from Continuing Operations for 10 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Income from Continuing Operations fell 279.02% year-over-year to -$3.7 million; the trailing twelve-month figure through Sep 2025 stood at -$13.0 million (down 43.01% YoY), and the FY2024 full-year result was -$7.2 million, up 18.96% from the prior year.
- Income from Continuing Operations improved to -$3.7 million in Q3 2025 per MYO's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at -$966409.0 in Q3 2024 and bottomed at -$4.6 million in Q2 2025.
- Historically, Income from Continuing Operations has averaged -$2.6 million across 5 years, with a median of -$2.8 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 65.14% in 2023, then sank 312.98% in 2025.
- Over 5 years, Income from Continuing Operations stood at -$2.9 million in 2021, then rose by 20.25% to -$2.3 million in 2022, then tumbled by 35.65% to -$3.2 million in 2023, then jumped by 60.23% to -$1.3 million in 2024, then plunged by 189.16% to -$3.7 million in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered -$3.7 million, -$4.6 million, and -$3.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Myomo | 54.96 Mn | 35.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -3.66 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -3.47 Mn |
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | -966,409.00 |
| Jun 30, 2024 | -1.12 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | -3.19 Mn |
| Sep 30, 2023 | -2.03 Mn |
| Jun 30, 2023 | -1.01 Mn |
| Mar 31, 2023 | -2.64 Mn |
| Dec 31, 2022 | -2.35 Mn |
| Sep 30, 2022 | -2.83 Mn |
| Jun 30, 2022 | -2.91 Mn |
| Mar 31, 2022 | -2.81 Mn |
| Dec 31, 2021 | -2.94 Mn |
| Sep 30, 2021 | -2.06 Mn |
| Jun 30, 2021 | -2.62 Mn |
| Mar 31, 2021 | -2.96 Mn |
| Dec 31, 2020 | -1.70 Mn |